Presentation is loading. Please wait.

Presentation is loading. Please wait.

InterstimTM for bowel dysfunction

Published byDomenic Brown Modified over 6 years ago

Similar presentations

Presentation on theme: "InterstimTM for bowel dysfunction"— Presentation transcript:

1 InterstimTM for bowel dysfunction
Project Update Randomized Crossover Trial of the Efficacy of Sacral Neuromodulation for Bowel Dysfunction following Sphincter Preserving Surgery Heather Yeo, MD, MHS Assistant Professor of Surgery and Healthcare Policy and Research 10/15/2016 I would like to thank the foundation for sponsoring my research

2 InterstimTM for bowel dysfunction
Background Many advances in the treatment of rectal cancer Over the last twenty years the management of rectal cancers has change significantly. Improvements in neoadjuvant chemoradiation, surgical technique including TME, and the development of improved stapling devices have led to increased rates of sphincter preservation.

3 InterstimTM for bowel dysfunction
Background National rate of sphincter preservation -- From <25% - >50%/20 years -- Up to 70% at specialized centers APR LAR VS. All of these changes have led an increased rate of sphincter preservation on a national level, from early reported rats of around 25% in the late 1980s to greater than 50% in by 2005, and even as high as 70% at specialized centers. For patients, means less permanent colostomies and more preservation of bowel continuity. Paquette et al. Dis Col Rect, 2010 Temple et al. Ann. Surg 2009

4 Low Anterior Resection Syndrome
>50% of patients Frequency/urgency Clustering Incontinence Incomplete evacuation While Interestingly with this increased rate of sps for low rectal tumors, we as physicians have see the sequalae that as patients often have symptoms of ---- Temple, 2012, SSO Presentation Peeters et al , J Clin Oncol, 2005

5 InterstimTM for bowel dysfunction
Options for treatment? Traditionally there hasn’t been much to offer All with poor results

6 Potential option for treatment
InterstimTM for bowel dysfunction Potential option for treatment Recent studies show improvement in benign causes of incontinence with the use of an implantable neuromodulating device FDA Approved 1997 for urinary incontinence 2011 for fecal incontinence

7 Sacral Nerve Stimulation
InterstimTM for bowel dysfunction Sacral Nerve Stimulation Stimulation of the sacral nerves (S3) Modulate the neural reflexes that influence the bladder, sphincter and pelvic floor Improves squeeze pressure, sensitivity, and rectal compliance

8 Potential Limitations of InterstimTM
InterstimTM for bowel dysfunction Potential Limitations of InterstimTM Phase II trial mostly benign disease Patients not radiated Patients without rectal resection May help incontinence, but what about the other bowel symptoms associated with LARS

9 InterstimTM for bowel dysfunction
Hypothesis The InterstimTM neuromodulating device will improve bowel function in rectal cancer patients after sphincter preserving surgery.

10 InterstimTM for bowel dysfunction
Primary Objective To evaluate the effectiveness of InterstimTM on improving bowel function following sphincter preserving surgery using BFI Secondary Objectives: Quality of Life, Satisfaction

11 InterstimTM for bowel dysfunction
Design Randomized Crossover Trial All patients with a successful trial receive the device Randomized to device on or off Washout Crossover device off/on Single Institution Pilot (10 patients funded by the AWSF), if successful plan to continue to multi-center study for a total of 76 pts

12 InterstimTM for bowel dysfunction
Progress to date Long IRB Process >10 months Trial opened in late 2014 at MSKCC Slow accrual (>100 patents approached) 4 Patients Enrolled IRB Approved at NYP-WCM Legal constraints delayed second Opening at NYP in 2 weeks – 3 patients ready for trial when open

13 InterstimTM for bowel dysfunction
Lessons Learned Early results are promising Patients are wary of device implantation and inability to have an MRI Multicenter trial will be needed We have 6 centers who are willing to collaborate if we go on to the next phase

14 Grant Funding Since AWSF Grant
InterstimTM for bowel dysfunction Grant Funding Since AWSF Grant Empire Clinical Research Investigators Program CADC Pilot Project Funding Society for Surgery of the Alimentary Tract Career Development Award Damon Runyon Clinical Investigator Kellen Junior Faculty Fellowship Laitman Clinical Scholar Award

15 InterstimTM for bowel dysfunction
Thank You Larissa Temple, MD Martin Weiser, MD Kelly Garrett, MD Kathleen Keenoy Karin Avila Jeff Milsom, MD Collaborators and Colleagues at MSK and Cornell Association of Women Surgeons Foundation/Ethicon, Inc.

16 Timing of Patient Reported Measures
InterstimTM for bowel dysfunction Timing of Patient Reported Measures

17 Results: Symptoms at 12 Months
Bowel Function after SPS Results: Symptoms at 12 Months Frequency Subscale Urgency Subscale Looking overall at our patients symptoms at 12 months we see that a large percentage of patients have symptoms. Dietary Subscale

18 Complications with Implantation
Interstim for bowel dysfunction Complications with Implantation

19 Complications with Test Stimulation
Interstim for bowel dysfunction Complications with Test Stimulation

20 Exclusion Criteria Recurrent/Metastatic Disease
Interstim for bowel dysfunction Exclusion Criteria Recurrent/Metastatic Disease Immune suppressive medication Seizure disorder Prior sacral/lower spinal surgery Congenital Spinal defect/Paraplegia Rectal prolapse IBD/Crohns Pregnancy Active anal/rectal abscess Pacemaker or other electronic implanted device Immediate need for MRI Patients will be excluded if the surgeon is unable to place the temporary stimulating lead. Inability to commit to local follow up for device management.

21 InterstimTM for bowel dysfunction
Recently this data was updated by Hull et al. Showing continued improvement at 5 years

22 Bowel Function Instrument
InterstimTM for bowel dysfunction Bowel Function Instrument 18 Item Instrument designed for patients who have had Sphincter Preserving Surgery Validated and used in several trials 3 Subscales Frequency Subscale Urgency Subscale Dietary Subscale Total Score=Bowel Function Index 0-100

23 InterstimTM for bowel dysfunction
SCHEMA

24 InterstimTM for bowel dysfunction
SCHEMA

25 InterstimTM for bowel dysfunction
SCHEMA

26 InterstimTM for bowel dysfunction
SCHEMA

27 InterstimTM for bowel dysfunction
SCHEMA

28 InterstimTM for bowel dysfunction
SCHEMA

29 InterstimTM for bowel dysfunction
SCHEMA

30 InterstimTM for bowel dysfunction
Phase II Trial Success rate at 12-months post implant

Download ppt "InterstimTM for bowel dysfunction"

Similar presentations

Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.

Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
CARBON ION THERAPY FOR SACRAL CHORDOMAS

CARBON ION THERAPY FOR SACRAL CHORDOMAS
The use of PTQ anal bulking injections

The use of PTQ anal bulking injections
Rectal Cancer: A Complete Clinical Response…Now what?

Rectal Cancer: A Complete Clinical Response…Now what?
Martha J. Morrell MD NeuroPace, Inc.

Martha J. Morrell MD NeuroPace, Inc.
Consequences of Treatment for Rectal Cancer Gillian Knowles, Rachel Haigh, Catriona McLean, Hamish Phillips, Malcolm Dunlop, Farhat Din.

Consequences of Treatment for Rectal Cancer Gillian Knowles, Rachel Haigh, Catriona McLean, Hamish Phillips, Malcolm Dunlop, Farhat Din.
Turning Questions into Trials: Innovation in Surgical Oncology Jennifer E. Rosen MD FACS Assistant Professor of Surgery and Molecular Medicine Boston University.

Turning Questions into Trials: Innovation in Surgical Oncology Jennifer E. Rosen MD FACS Assistant Professor of Surgery and Molecular Medicine Boston University.
ACRIN 6687 A Phase 2, Multicenter Evaluation of 18 F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant.

ACRIN 6687 A Phase 2, Multicenter Evaluation of 18 F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant.
Overactive Bladder: Diagnosis and Treatment Chase Kenyon Sovell, MD Urology Associates May 30 th, 2007 Pearls of Plumbing Seminar.

Overactive Bladder: Diagnosis and Treatment Chase Kenyon Sovell, MD Urology Associates May 30 th, 2007 Pearls of Plumbing Seminar.
Urinary incontinence in women October 2006. Changing clinical practice NICE guidelines are based on the best available evidence The Department of Health.

Urinary incontinence in women October Changing clinical practice NICE guidelines are based on the best available evidence The Department of Health.
Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.
Slawomir Marecik, MD, FACS, FASCRS Advocate Lutheran General Hospital, Park Ridge, IL Clinical Assistant Professor University of Illinois, Chicago, USA.

Slawomir Marecik, MD, FACS, FASCRS Advocate Lutheran General Hospital, Park Ridge, IL Clinical Assistant Professor University of Illinois, Chicago, USA.
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.

Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Seeking Patients for Back Pain Study DIAM ™ Spinal Stabilization System vs. Conservative Care Therapies Wayne Cheng, MD Caution: Investigational device,

Seeking Patients for Back Pain Study DIAM ™ Spinal Stabilization System vs. Conservative Care Therapies Wayne Cheng, MD Caution: Investigational device,
Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer.

Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer.
Role of surgery in treatment of fecal incontinence disorders Rasoul Azizi M.D Colo-Rectal Surgeon Associate Professor of surgery School of Medical Sciences,

Role of surgery in treatment of fecal incontinence disorders Rasoul Azizi M.D Colo-Rectal Surgeon Associate Professor of surgery School of Medical Sciences,
Experiences in Sacral Neuromodulation for the Treatment of Fecal Incontinence Stephen Cohen, MD, FACS, FASCRS Associate Clinical Professor Emory University.

Experiences in Sacral Neuromodulation for the Treatment of Fecal Incontinence Stephen Cohen, MD, FACS, FASCRS Associate Clinical Professor Emory University.
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.

Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.

Similar presentations

Ads by Google